KENILWORTH, NJ — June 28, 2002 —
Schering-Plough Corporation announced today that Clarinex 5 mg Reditabs, a rapidly disintegrating tablet formulation of the nonsedating antihistamine desloratadine, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of allergy symptoms caused by perennial indoor and seasonal outdoor allergens and chronic idiopathic urticaria (CIU), or hives of unknown cause, in adults and children 12 years of age and older.
Clarinex Reditabs follows Clarinex 5 mg Tablets as the second formulation of Clarinex to be
approved by the FDA. The company plans to launch the product pending FDA approval of a quality control test revision, the supplement for which has already been submitted, and the build-up of sufficient inventories. Scherer DDS Ltd. manufactures Clarinex Reditabs for Schering-Plough.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!